Within this clinical trial, we will investigate whether the administration of the TSPO ligand etifoxine in addition to treatment as usual (TAU) changes the time course or the extent of the therapeutic response in patients with severe unipolar/bipolar depression. This evidence concerns the gene TSPO and bipolar disorder.